Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 8,059 $ 15,045
Prepaid expenses and other current assets 897 1,381
Total Current Assets 8,956 16,426
Property and equipment, net 251 367
Right of use asset 352 419
Deposits and other assets 23 23
Total Assets 9,582 17,235
Current Liabilities:    
Accounts payable 1,025 2,315
Accrued expenses 1,209 1,776
Accrued employee benefits 927 935
Lease liability 268 249
Total Current Liabilities 3,429 5,275
Lease liability - long term 334 473
Total Liabilities 3,763 5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,669 12,544
Stockholders' Deficit:    
Common Stock, $0.001 par value; 200,000,000 shares authorized, 18,646,152 and 16,808,758 issued and 18,643,824 and 16,806,430 outstanding 19 17
Additional paid-in capital 234,860 232,580
Accumulated deficit (242,289) (235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (3,966) 1,821
Non-controlling interest (2,884) (2,878)
Total Stockholders' Deficit (6,850) (1,057)
Total Liabilities and Stockholders' Deficit 9,582 17,235
Series B Preferred Stock [Member]    
Stockholders' Deficit:    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 5,525 issued and outstanding and 7,638 issued and outstanding 3,444 4,761
Total Stockholders' Deficit $ 3,444 $ 4,761